Every material Form 8-K IQVIA filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IQVIA Holdings entered into Amendment No. 5 to its Fifth Amended and Restated Credit Agreement on December 9, 2025. The amendment refinances existing term and revolving loans into new classes, removes the term SOFR credit spread adjustment on U.S. dollar term A and revolving loans to lower their interest rate, and releases the Swiss Subsidiary Borrower and the Japanese Borrower from their obligations under the agreement. The filing does not state dollar amounts, so the size of the financial effect is not disclosed.
Agreement amended on December 9, 2025, covering the Fifth Amended and Restated Credit Agreement
Term A-1, Term A-2 and Term A Euro loans, plus U.S., Japanese and Swiss/Multicurrency revolving commitments, refinanced into new classes
Term SOFR credit spread adjustment eliminated on U.S. dollar term A and revolving loans, lowering their interest rate
Swiss Subsidiary Borrower and Japanese Borrower released from all borrower obligations
IQVIA's board appointed Dr. William G. Kaelin Jr. as a director effective November 5, 2025, and the board determined he is independent under New York Stock Exchange rules. The filing discloses a board addition only and contains no financial results or guidance.
Dr. William G. Kaelin Jr. appointed to the board on November 5, 2025
Board determined Dr. Kaelin meets the NYSE definition of independent director
He will receive non-employee director compensation and sign the standard indemnification agreement
Dr. Kaelin shared the 2019 Nobel Prize in Physiology or Medicine and serves on the board of Eli Lilly and Company
IQVIA reported third-quarter 2025 results on October 28, 2025, with revenue of $4.1 billion, up 5.2% from a year earlier, and GAAP net income of $331 million, up from $285 million. The company reaffirmed the midpoint of its full-year 2025 guidance and narrowed its revenue, Adjusted EBITDA and Adjusted diluted EPS ranges. Adjusted EBITDA rose 1.1% to $949 million, slower than revenue growth, but the headline revenue and per-share measures improved.
Q3 revenue was $4,100 million, up 5.2% on a reported basis from $3,896 million in Q3 2024.
GAAP diluted EPS was $1.93, up from $1.55; Adjusted diluted EPS was $3.00, up from $2.84.
Full-year 2025 guidance: revenue $16,150 million to $16,250 million; Adjusted EBITDA $3,775 million to $3,800 million; Adjusted diluted EPS $11.85 to $11.95.
Free cash flow was $772 million, up 35% year-over-year.
IQVIA said Michael J. Fedock, currently Senior Vice President of Financial Planning and Analysis, will become Executive Vice President and Chief Financial Officer effective February 28, 2026. Ronald E. Bruehlman will retire as CFO on that date and become Senior Advisor to CEO Ari Bousbib, which the company said is part of a previously announced CFO succession plan.
Michael J. Fedock, age 50, succeeds Ronald E. Bruehlman as CFO effective February 28, 2026.
Fedock's base salary will rise to $750,000, with an annual cash incentive target of 100% of base salary.
Bruehlman will move to Senior Advisor to CEO Ari Bousbib, effective the same date.
The filing does not report any financial results or guidance changes.
IQVIA reported second-quarter 2025 revenue of $4,017 million, up 5.3% from a year earlier, and adjusted diluted earnings per share of $2.81, up from $2.64. GAAP net income fell to $266 million from $363 million, and the company issued updated full-year 2025 guidance of $16.1 billion to $16.3 billion in revenue and $11.75 to $12.05 in adjusted diluted EPS. The filing does not show the prior guidance, so the direction of the guidance change cannot be determined from this document.
Q2 revenue of $4,017 million, up 5.3% reported and 3.6% at constant currency
GAAP diluted EPS of $1.54 versus $1.97 a year earlier; adjusted diluted EPS of $2.81 versus $2.64
Full-year 2025 guidance: revenue $16,100 million to $16,300 million; adjusted diluted EPS $11.75 to $12.05
Repurchased $607 million of common stock in Q2; $1,981 million of authorization remained as of June 30, 2025
IQVIA's wholly owned subsidiary IQVIA Inc. completed a $2.0 billion sale of 6.250% senior unsecured notes maturing June 1, 2032. Proceeds will mainly repay borrowings under its revolving credit facility, with the rest covering offering fees and general corporate purposes, so the filing shows a refinancing of existing debt rather than new spending.
Gross proceeds of $2,000,000,000 from 6.250% senior notes due June 1, 2032
Interest payable semi-annually on June 1 and December 1, starting December 1, 2025
Proceeds to repay existing revolving credit facility borrowings and pay offering fees and expenses
Issued under an indenture dated June 4, 2025, with U.S. Bank Trust Company, National Association, as trustee
IQVIA reported first-quarter 2025 results on May 6, 2025, with revenue up 2.5% to $3,829 million, while GAAP net income fell to $249 million from $288 million a year earlier. The company raised its full-year 2025 revenue guidance by $275 million on more favorable foreign currency rates and reaffirmed its Adjusted EBITDA and Adjusted Diluted EPS guidance, so shareholders see higher sales and adjusted profit alongside lower GAAP earnings.
Revenue of $3,829 million, up 2.5% reported and 3.5% at constant currency from $3,737 million
GAAP diluted EPS of $1.40 versus $1.56, and GAAP net income of $249 million versus $288 million
Adjusted Diluted EPS of $2.70, up 6.3%, and Adjusted EBITDA of $883 million, up 2.4%
Full-year 2025 revenue guidance raised to $16,000 million to $16,400 million; profit guidance reaffirmed
IQVIA Holdings entered into Amendment No. 4 to its Fifth Amended and Restated Credit Agreement on March 10, 2025. The amendment creates new term B dollar loans used to refinance Term B-4 Dollar Loans at a lower margin and to repay Term B-2 Euro Loans in full. The filing does not state the loan amounts, so the size of the change in borrowing costs cannot be determined from it.
Term B-4 Dollar Loans refinanced; margin cut from SOFR plus 2.00% to SOFR plus 1.75% per annum
Term B-2 Euro Loans to be repaid in full under the amendment
Amendment dated March 10, 2025; administrative agent is Bank of America, N.A.
Filing does not disclose principal amounts of the new or repaid loans
IQVIA reported fourth-quarter 2024 revenue of $3,958 million, up 2.3% on a reported basis, and adjusted diluted EPS of $3.12, up 9.9%. GAAP diluted EPS fell 4.7% to $2.42, and the company reaffirmed its 2025 outlook while raising its share repurchase authorization by $2.0 billion to $3.013 billion.
Q4 2024 revenue was $3,958 million, up 2.3% reported and 3.0% at constant currency; full-year revenue was $15,405 million, up 2.8%.
Q4 GAAP net income was $437 million, down 6.8%; adjusted diluted EPS was $3.12, up 9.9%.
2025 guidance reaffirmed: revenue of $15,725 million to $16,125 million and adjusted diluted EPS of $11.70 to $12.10.
Board increased share repurchase authorization by $2,000 million on February 5, 2025; full-year 2024 repurchases totaled $1,350 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IQVIA filing is on SEC EDGAR ↗. 8-K briefs of other companies →